

DOCUMENT CONTROL SUMMARY

Title of Document	LSESN Pathway for Head & Neck Sarcomas (Adults)
Aims	To agree the pathway for adult patients presenting with suspected or confirmed head and neck sarcomas within the London and South-East Sarcoma Network
Issued by	London and South-East Sarcoma Network (LSESN) Sarcoma Advisory Group (SAG)
Circulation To	LSESN SAG: <ul style="list-style-type: none">• Core members• Trust Sarcoma Leads• Designated Practitioners• Cancer Alliances for distribution to head and neck cancer MDTs within the LSESN
Author/s	Subgroup of LSESN SAG
Date of Version	December 2024
Version Number	2
Approved By	LSESN SAG
Approval Date	06/12/2024 (SAG Meeting)
Outstanding Items	None
Date of Review	December 2026
Storage Pathway	https://www.lsesn.nhs.uk/sarcoma.html


LSESN Adult Head and Neck Sarcoma Pathway

Introduction

This guidance is to provide direction for the management of adult patients with sarcomas that may present through Head and Neck cancer services and to define the relationship that should exist with the specialist sarcoma MDT. There is a separate pathway for children, teenagers and young adults which can be found on the LSESN website. The guidance refers to the care of adult patients in the London and South East Sarcoma Network and therefore recognises that specialist services for soft tissue sarcomas are provided by the Sarcoma Unit at The Royal Marsden Hospital and the London Sarcoma Service, through joint working of UCLH and RNOH. All bone sarcomas are managed by the London Sarcoma Service. Superficial scalp sarcomas should be managed by skin sarcoma pathways.

The local control rate for intermediate and high-grade soft tissue sarcoma of the head and neck is markedly inferior to that of sarcoma of the limbs. Therefore, it is highly critical that all new cases of head and neck sarcoma should be discussed at a sarcoma MDT at the earliest opportunity so that patients receive the optimal treatment.

Guidance for referrers



Principles, consistent with the [national sarcoma service specification](#)

- All people with a suspected or confirmed diagnosis of sarcoma must be referred to a Specialist Sarcoma Centre
- The principal role of a Sarcoma MDT is to determine a care plan for all people with bone and soft tissue sarcoma and to be responsible for its delivery either by members based at the Specialist Sarcoma Centre or by designated practitioners working at Local Sarcoma Units or by Children/Teenage and Young Adult Principal Treatment Centres following care pathways agreed by the Sarcoma Advisory group
- Pathology for all sarcomas must be reviewed by a Specialist Sarcoma Pathologist for diagnostic confirmation and undertaking any appropriate molecular analysis and genomic testing
- If possible, when biopsy or resection is undertaken, tissue must be frozen for whole genome sequencing
- Sarcoma services must be structured and managed to reduce the number of unplanned excisions
- All resections of sarcomas are undertaken by surgeons who are core or designated members of the Sarcoma MDT. Surgery for bone and soft tissue sarcoma arising in the head and neck must only be carried out by designated practitioners in centres defined by the Sarcoma Advisory Group
- People with suspected head and neck sarcoma must be referred, according to LSESN guidelines, to a designated diagnostic centre, which will be a Sarcoma Specialist Centre where head and neck and sarcoma MDTs work jointly


Additional background evidence supporting specialist care

- Presentation to a specialised sarcoma multidisciplinary tumour board is independently correlated with reduction in the risk of relapse¹
- Surgery in a sarcoma reference centre has been reported to be associated with improved local recurrence free survival, event free survival and overall survival^{2,3}


¹ Ann Oncol 2017;28(11):2852-2859

² Ann Oncol 2019;30:1143-1153

³ Ann Oncol 2024;35(4): 351-363



LSESN Head and Neck Adult Soft Tissue Sarcoma Pathway (RMH and UCLH)



Directory of Contacts

RMH (soft tissue sarcomas)

To refer a patient please email rmh-tr.referrals@nhs.net

To discuss the referral please contact:

Dr Aisha Miah	Consultant Clinical Oncologist	sarcoma.oncology@nhs.net 0207 808 2591 (PA)
Dr Shane Zaidi	Consultant Clinical Oncologist	sarcoma.oncology@nhs.net 0207 808 2591 (PA)
Prof Cyrus Kerawala	Consultant Surgeon	cyrus.kerawala@rmh.nhs.uk
Prof Vin Paleri	Consultant Surgeon	vinidh.paleri@rmh.nhs.uk
24/7 on call sarcoma consultant (via switchboard)		020 7352 8171
Sarcoma MDT Coordinator		0207 811 8078

UCLH (bone and soft tissue sarcomas)

To refer a patient please email the [referral form](#) to uclh.tr.sarcomareferrals@nhs.net

To discuss the referral please contact:

Dr Franel Le Grange	Consultant Clinical Oncologist	uclh.oncology.sarcomaradiotherapy.admin@nhs.net 020 3447 9866 (PA)
Dr Vasilios Karavasilis	Consultant Medical Oncologist	uclh.oncology.sarcoma.admin@nhs.net 020 3447 9346 (PA)
Mr Nick Kalavrezos	Consultant Surgeon	n.kalavrezos@nhs.net 020 3447 2159
Ms Deepti Sinha	Consultant Surgeon	deeptisinha@nhs.net
24/7 on call sarcoma consultant (via switchboard)		020 3456 7890
Sarcoma MDT Coordinator		020 3447 4821/4418

Designated Practitioners (see Appendix 2 of Sarcoma Service Specification 170122S)

A list of Chemotherapy and Radiotherapy Designated Practitioners and their contact details can be found on the LSESN website <https://www.lsesn.nhs.uk/guidelines.html>

A list of surgical designated practitioners can be found below:

Name	Role	Trust	Email & Tel no.
Nick Kalavrezos	Consultant Surgeon - OMFS	UCLH	n.kalavrezos@nhs.net
Deepti Sinha	Consultant Surgeon - OMFS	UCLH	deeptisinha@nhs.net
Jonathan Joseph	Consultant Surgeon- ENT	UCLH	j.joseph4@nhs.net
Francis Vaz	Consultant Surgeon- ENT	UCLH	francis.vaz1@nhs.net
Vin Paleri	Consultant Surgeon - ENT	RMH	vinidh.paleri@rmh.nhs.uk
Cyrus Kerawala	Consultant Surgeon - OMFS	RMH	cyrus.kerawala@rmh.nhs.uk